Zentiva (SCD) investor relations material

Executive summary

• Revenue increased to RON 271.3m for Q1 2025, up 1.9% year-over-year; net profit declined to RON 55.2m from RON 74.2m in Q1 2024.

• Operating profit fell to RON 54.9m from RON 75.2m year-over-year, mainly due to higher raw material and employee expenses.

• Market capitalization as of March 31, 2025, was RON 3.15bn, with 697m shares outstanding.

Financial highlights

• Revenue from sales of goods and services reached RON 271.3m, up from RON 266.3m year-over-year.

• Net profit dropped 25.5% year-over-year to RON 55.2m; EPS was RON 0.08 vs. RON 0.11.

• Operating profit margin decreased due to higher costs in raw materials, employee benefits, and support services.

• Cash and cash equivalents increased to RON 45.7m from RON 33.6m at year-end 2024.

• Net cash from operating activities was RON 18.5m, down from RON 40.5m in Q1 2024.

Outlook and guidance

• Management expects positive cash flows and increased sales and profitability in 2025, driven by direct distribution of generic medicines.

• The company is considered a going concern, with forecasts supporting continued operations.